

 **#CARDIOTOX** **CARDIOTOX.ES**

CARDIOTOX 26

12-13 NOVEMBER
MADRID



VENUE

Meeting Place Castellana 81, Madrid

QUANTITATIVE IMAGING IN CARDIO-ONCOLOGY: FROM IMAGING BIOMARKERS TO CLINICAL IMPLEMENTATION

14:15h-15:45h - 13th November 2026 - Room 1

Sponsored by Philips

PHILIPS

Cardio-oncology imaging is moving beyond isolated markers and prototype-driven research towards integrated, quantitative and clinically scalable pathways. This workshop will focus on how advanced echocardiographic and CMR biomarkers can improve risk stratification, support earlier detection of myocardial dysfunction, and strengthen longitudinal follow-up in routine practice. The core concept is practical integration: quantitative echocardiography as the scalable front-line tool, with CMR providing complementary phenotyping and clarification when needed.

Objectives

- Review the clinical value of quantitative imaging in cardio-oncology beyond conventional LVEF assessment.
- Discuss how advanced echocardiographic and CMR biomarkers can refine risk stratification, enable earlier detection of cardiotoxicity, and support longitudinal follow-up.
- Demonstrate, through case-based discussion, how imaging innovations can be integrated into routine cardio-oncology practice.

Programme

Introduction

- **Short strategic introduction**
- **Innovation in Cardio-Oncology imaging**
- **Interactive case-based forum: quantitative imaging biomarkers in cardio-oncology**
 - Baseline risk refinement before potentially cardiotoxic therapy
 - Early detection of subclinical dysfunction during treatment
 - Escalation from quantitative echo to CMR when uncertainty remains or deeper phenotyping is needed
 - Hands-on Stations

CARDIOTOX 26

12-13 NOVEMBER
MADRID



Secretaría técnica

 **tactics**

 Barcelona · Madrid

 93 451 17 24

 info@tacticsmd.net

 www.tacticsmd.net